PubMed:23528904 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":76},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":77,"end":157},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":158,"end":297},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":298,"end":433},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":434,"end":556},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":76},"obj":"Sentence"},{"id":"T2","span":{"begin":77,"end":157},"obj":"Sentence"},{"id":"T3","span":{"begin":158,"end":297},"obj":"Sentence"},{"id":"T4","span":{"begin":298,"end":433},"obj":"Sentence"},{"id":"T5","span":{"begin":434,"end":556},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":54,"end":58},"obj":"gene:4613"},{"id":"T1","span":{"begin":33,"end":46},"obj":"disease:C0027819"},{"id":"T2","span":{"begin":54,"end":58},"obj":"gene:4613"},{"id":"T3","span":{"begin":33,"end":46},"obj":"disease:C0700095"},{"id":"T4","span":{"begin":54,"end":58},"obj":"gene:4613"},{"id":"T5","span":{"begin":69,"end":75},"obj":"disease:C0028259"},{"id":"T6","span":{"begin":77,"end":81},"obj":"gene:4613"},{"id":"T7","span":{"begin":99,"end":112},"obj":"disease:C0700095"},{"id":"T8","span":{"begin":77,"end":81},"obj":"gene:4613"},{"id":"T9","span":{"begin":99,"end":112},"obj":"disease:C0027819"},{"id":"T10","span":{"begin":379,"end":383},"obj":"gene:4613"},{"id":"T11","span":{"begin":334,"end":356},"obj":"disease:C1135161"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":99,"end":112},"obj":"HP_0003006"},{"id":"T2","span":{"begin":343,"end":356},"obj":"HP_0003006"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"23528904-0#54#58#gene4613","span":{"begin":54,"end":58},"obj":"gene4613"},{"id":"23528904-0#33#46#diseaseC0027819","span":{"begin":33,"end":46},"obj":"diseaseC0027819"}],"relations":[{"id":"54#58#gene461333#46#diseaseC0027819","pred":"associated_with","subj":"23528904-0#54#58#gene4613","obj":"23528904-0#33#46#diseaseC0027819"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}

{"project":"PubCasesHPO","denotations":[{"id":"AB1","span":{"begin":99,"end":112},"obj":"HP:0003006"},{"id":"TI1","span":{"begin":33,"end":46},"obj":"HP:0003006"},{"id":"AB2","span":{"begin":343,"end":356},"obj":"HP:0003006"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}

{"project":"PubCasesORDO","denotations":[{"id":"AB1","span":{"begin":99,"end":112},"obj":"ORDO:635"},{"id":"TI1","span":{"begin":33,"end":46},"obj":"ORDO:635"},{"id":"AB2","span":{"begin":343,"end":356},"obj":"ORDO:635"}],"namespaces":[{"prefix":"ORDO","uri":"http://www.orpha.net/ORDO/Orphanet_"}],"text":"Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.\nMYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression."}